Navigation Links
EpiCept Corp. Joins OTCQX

NEW YORK, Sept. 19, 2011 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), the company that operates the world's largest electronic marketplace for broker-dealers to trade unlisted stocks, today announced that EpiCept Corp. (OTCQX: EPCT), a specialty pharmaceutical company, is now trading on the OTC market's highest tier, OTCQX®.


EpiCept began trading today on the OTC market's prestigious tier, OTCQX U.S. Investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on and

"EpiCept has chosen to remain investor focused as they transition to trade on OTCQX, which allows them to continue to provide superior information and transparent trading on the quality-controlled OTCQX platform," said R. Cromwell Coulson, President and Chief Executive Officer of OTC Markets Group. "We are pleased to welcome EpiCept to OTCQX."

Rodman & Renshaw, LLC will serve as EpiCept's Designated Advisor for Disclosure ("DAD") on OTCQX, responsible for providing guidance on OTCQX requirements.

About EpiCept Corp.

EpiCept Corp. (OTCQX: EPCT) trades in the United States on OTCQX under the symbol "EPCT". EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and pain. The Company's lead product is Ceplene®, approved in the EU and Israel for the remission maintenance and prevention of relapse in adult patients with AML in first remission.  The Company has two other oncology drug candidates currently in clinical development that were discovered using in-house technology and have been shown to act as vascular disruption agents in a variety of solid tumors. The Company's pain portfolio includes AmiKet™, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies.

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates the world's largest electronic marketplace for broker-dealers to trade unlisted stocks.  Our OTC Link™ platform supports an open network of competing broker-dealers that provide investors with the best prices in over 10,000 OTC securities.  We categorize the wide spectrum of OTC companies into three tiers - OTCQX (the quality-controlled marketplace for investor friendly companies), OTCQB® (the U.S. reporting company marketplace for development stage companies), and OTC Pink™ (the speculative trading marketplace) - so investors can identify the level and quality of information companies provide.  To learn more about how OTC Markets Group makes the unlisted markets more transparent, informed, and efficient, visit

Subscribe to the OTCQX RSS Feed

SOURCE OTC Markets Group Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. EpiCept Provides Update on Clinical and Regulatory Progress with Ceplene(TM) and EpiCept(TM) NP-1 Cream
2. EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407
3. EpiCept Reports Regulatory Progress on Ceplene(TM)
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX®
6. Cantel Medical Corp. to Present at the CL King 9th Annual Best Ideas Conference
7. China Nuvo Solar Target Acquisition SurgLine Updates OptiMedical Corp.s Sales Forecast in Excess of $10,000,000
8. BioSpecifics Technologies Corp. Reports Second Quarter 2011 Financial Results
9. Novo Nordisk and Partnership of Ivy Equities, LCOR and Intercontinental RE Corp. Announce Lease Agreement for N.J. Pharmaceutical Companys New U.S. Headquarters
10. China Nuvo Solar Target Acquisition SurgLine Announces Third-Party Distribution Agreement With OptiMedical, Corp.
11. BioSpecifics Technologies Corp. Announces Board Authorization of up to $2 Million Share Repurchase Program
Post Your Comments:
(Date:11/27/2015)... 2015  Lannett Company, Inc. (NYSE: LCI ... acquisition of Kremers Urban Pharmaceuticals Inc. (KU), the ... company UCB S.A. (Euronext: UCB). ... KU from UCB for total consideration of approximately ... customary working capital adjustment, a deduction of certain ...
(Date:11/27/2015)... 26, 2015 ... the "2016 Global Tumor Marker Testing ... and Sales Segment Forecasts, Innovative Technologies, Instrumentation ... to their offering. --> ... "2016 Global Tumor Marker Testing Market: ...
(Date:11/26/2015)... Un nuevo enfoque combina la ... cáncer avanzado.   --> Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... --> Clinical Cancer Research . --> ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... An inventor, from Hopkinsville, Ky., thought there ... home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. provides ... so, it could help to prevent potential overdose situations. As a result, it ...
(Date:11/27/2015)... Aliso Viejo, CA (PRWEB) , ... November 27, 2015 , ... ... exclusively for use in Final Cut Pro X. With ProSidebar: Fasion, video editors ... banners, or use ProSidebar as a minimalist title opener. Utilize presets featuring self-animating ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television ... an interesting show that delves into an array of issues that are presently affecting ... benefit from open dialogue, this show is changing the subjects consumers focus on, one ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and ... nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown commitment ... advance the healthcare industry as a whole through their advocacy and professional efforts. ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point ... come together on Thanksgiving Day to share the things that they are most ... Serenity Point YouTube channel, patients displayed what they wrote on index cards, describing ...
Breaking Medicine News(10 mins):